Gut Microbiome Research Breakthroughs in Digestive Health

What if our microbes were constantly broadcasting their metabolic activity in a language we could learn to read? Over the past decade, VOC analysis has moved from an esoteric laboratory technique toward a practical window on some of the most interesting findings in modern gut microbiome research.

Recent years have delivered findings that challenge conventional assumptions about digestive health and how it can be monitored. From the gut-brain axis to cancer immunotherapy response, from phage biology to engineered microbial consortia, the field is at an inflection point. This article surveys those breakthroughs, with the studies and the numbers attached, and what they might mean for precision medicine.

Area	Landmark finding	Study	Status
Gut-brain axis	Faecalibacterium and Coprococcus consistently depleted in depression across two large population cohorts	Valles-Colomer et al., Nature Microbiology, 2019	Association in observational data
Immune education	Toll-like receptor recognition of commensal microflora is required for intestinal homeostasis	Rakoff-Nahoum et al., Cell, 2004	Established mechanism in mice
Cancer immunotherapy	Responders to anti-PD-1 in melanoma show higher gut microbial diversity and distinct taxa; responder stool improves tumor control in germ-free mice	Gopalakrishnan et al. and Matson et al., Science, 2018	Replicated association plus animal causal evidence
Metabolic disease	A defined high-fiber diet enriched a guild of short-chain fatty acid producers; 89% of the intervention group reached HbA1c below 7% versus 50% of controls	Zhao et al., Science, 2018	Randomized clinical trial
Targeted metabolites	10 g per day of an inulin-propionate ester delivered propionate to the colon and reduced weight gain over 24 weeks	Chambers et al., Gut, 2015	Randomized controlled trial
Microbiota transfer	An oral spore-based microbiome therapeutic cut recurrence of C. difficile infection to 12% versus 40% on placebo	Feuerstadt et al., NEJM, 2022	Phase 3 randomized trial
Probiotic limits	Mucosal colonization by an eleven-strain probiotic is person-specific and often absent; stool shedding does not indicate colonization	Zmora et al., Cell, 2018	Endoscopically sampled human study

The Gut-Brain Axis

Few areas have captured as much attention as the gut-brain axis. For decades we understood that the central nervous system influences gut function. The recognition that the reverse is also true has been transformative.

The strongest human population evidence comes from Valles-Colomer and colleagues, who analyzed the Flemish Gut Flora Project cohort of 1,054 individuals and validated the findings in 1,063 participants from the Dutch LifeLines DEEP cohort. Two butyrate-producing genera, Faecalibacterium and Coprococcus, were consistently depleted in people reporting depression, including after correcting for antidepressant use. The authors also built a catalogue of the neuroactive potential of gut bacteria, mapping which taxa carry the pathways to produce or degrade neurotransmitter-related compounds (Nature Microbiology, 2019). This is an association in observational data, and the authors are careful to say so.

Mechanistic evidence comes largely from animal work. Studies using germ-free mice show measurable changes in behavior, anxiety-related responses and social engagement when specific microbial communities are introduced, and butyrate-producing bacteria influence host histone deacetylase activity and therefore gene expression (Sommer and Backhed, Nature Reviews Microbiology, 2013). This is not metaphor; it is biochemistry.

Work on specific signaling molecules has added precision. Bhattarai and colleagues showed that gut microbiota-produced tryptamine activates an epithelial G-protein-coupled receptor and increases colonic secretion, which is a fully specified route from a microbial metabolite to a physiological effect (Cell Host & Microbe, 2018). Whether biomarker discovery in this area will support earlier intervention in mood disorders is a research question, not a settled result.

Immunity and Microbial Immune Modulation

The intersection of gut microbiome research and immunology has produced some of the most clinically actionable findings of recent years. The microbiota functions as an educator of the adaptive immune system, and dysbiosis can impair immune tolerance.

The foundational demonstration is now two decades old. Rakoff-Nahoum and colleagues showed that recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis, and that mice lacking that signaling were markedly more susceptible to chemically induced colitis (Cell, 2004). The commensal community is not tolerated by the immune system so much as actively read by it. Thaiss and colleagues later synthesized how the microbiome and innate immunity are coupled through pattern recognition, inflammasome signaling and metabolite sensing (Nature, 2016).

Specific organisms matter. Faecalibacterium prausnitzii is depleted in Crohn's disease, and Sokol and colleagues showed that both the organism and its cell-free culture supernatant reduced inflammation in experimental colitis and corrected dysbiosis in a mouse model (PNAS, 2008). That is one of the clearest cases where an abundance association was followed by a functional test.

The connection to VOC analysis is direct. Butyrate acts as a histone deacetylase inhibitor that supports regulatory T cell development and epithelial barrier function (Parada Venegas et al., Frontiers in Immunology, 2019). Monitoring volatile profiles therefore assesses immune-relevant aspects of microbial function non-invasively. What has not been established is that dysbiotic volatile profiles reliably precede immune dysfunction in a way that supports clinical action.

The Microbiome and Cancer Immunotherapy

Perhaps the most clinically consequential area involves the microbiota's influence on response to checkpoint inhibitor immunotherapy, and here two independent teams published in the same issue of Science in 2018.

Gopalakrishnan and colleagues profiled the oral and gut microbiome of 112 patients with metastatic melanoma receiving anti-PD-1 therapy. Responders showed significantly higher gut microbial diversity and enrichment of Ruminococcaceae, and germ-free mice receiving fecal transplants from responders showed improved tumor control and enhanced T cell responses. Matson and colleagues, working independently in a separate melanoma cohort, found a different set of species enriched in responders, including Bifidobacterium longum, Collinsella aerofaciens and Enterococcus faecium, again with transferable effects in germ-free mice.

Both results point the same way and name different organisms. That discrepancy is itself the finding: the association with response appears robust, while the specific taxonomic signature is not consistent between cohorts. Any recommendation engine built on this literature should encode both facts.

Tilg and colleagues review the parallel case in colorectal cancer, where Fusobacterium nucleatum and other organisms are enriched in tumor tissue and appear to influence both carcinogenesis and treatment response (Cancer Cell, 2018). The role of volatile compounds in treatment response is still being characterized, though the possibility of non-invasive metabolomic signatures relevant to it is an obvious direction.

Metabolic Disease Connections

Research linking dysbiosis to metabolic disease has matured considerably, moving beyond association toward intervention. Type 2 diabetes offers the clearest example.

Zhao and colleagues ran a randomized clinical trial in which participants with type 2 diabetes received a diet high in diverse fermentable fibers. Of 141 strains of short-chain fatty acid producers detected, only 15 responded to the fiber intervention, forming what the authors described as a guild. Promoting that guild was associated with markedly better glycemic control: 89 percent of the intervention group reached an HbA1c below 7 percent at the end of the intervention, compared with 50 percent of controls (Science, 2018). This is a controlled dietary intervention with a hard clinical endpoint, not a correlation.

The mechanism has also been tested directly. Chambers and colleagues delivered propionate specifically to the colon using an inulin-propionate ester at 10 grams per day. Acute administration increased postprandial PYY and GLP-1 release and reduced energy intake; over 24 weeks in overweight adults it significantly reduced weight gain and intra-abdominal adipose tissue relative to inulin control (Gut, 2015). Naming what the literature used is not a recommendation to take it, and inulin at that dose commonly causes bloating and flatulence, particularly at the start.

The proposed pathway from dysbiosis to metabolic dysfunction is becoming clearer: reduced butyrate leads to diminished intestinal barrier function, increased translocation of bacterial components, and chronic low-grade inflammation that manifests as insulin resistance. Dysbiotic communities also produce altered profiles of secondary bile acids and trimethylamine.

What continuous VOC monitoring could offer here is feedback on whether a microbiota-modulating intervention is producing the intended metabolic shift, rather than waiting months for downstream clinical markers to move. For the wider scientific context, see our overview of gut microbiome science and VOC analysis.

Beyond Bacteria: The Virome and Mycobiome

One of the more exciting recent developments is a growing appreciation for the non-bacterial members of the gut ecosystem. The field was bacteria-centric for a long time, and that focus missed important aspects of gut ecology.

The bacteriophage community has emerged as a substantial regulator of bacterial diversity and function. Research suggests that phage composition shifts markedly in dysbiotic states, sometimes reinforcing dysbiosis by selectively lysing beneficial bacteria, while in healthy individuals the phage community appears to help maintain diversity by preventing overgrowth of dominant species.

The fungal community, or mycobiome, tells a related story, and here the scale has been measured. Nash and colleagues analyzed the mycobiome of the Human Microbiome Project healthy cohort and found that fungi make up a very small fraction of gut microbial sequences, with a low-diversity community dominated by Saccharomyces, Malassezia and Candida, and considerable variability between individuals and over time (Microbiome, 2017). Small biomass does not mean small effect: fungal cell wall components activate distinct pattern recognition receptors and shape the balance between inflammatory and regulatory immune responses.

These findings expand what a healthy microbiota means. It is not simply having the right bacteria; it is maintaining appropriate relationships among bacteria, phages and fungi.

Next-Generation Therapeutics

Phage Therapy

Bacteriophage therapy, long considered experimental, is entering clinical evaluation for specific dysbiotic indications. The advantage over conventional probiotics is precision. Rather than introducing a beneficial bacterium and hoping it establishes, phage therapy introduces specific predators that reduce target bacteria, creating space for other community members to expand. Several trials are underway with preliminary data described as encouraging, and it should be emphasized that this remains investigational.

Engineered Consortia

Engineered microbial consortia represent another frontier. Rather than attempting to restore an entire microbiota to some ideal state we cannot actually specify, this approach designs minimal communities that perform defined functions: butyrate production, secondary bile acid metabolism, or immune tolerance induction.

This is not purely theoretical any more. SER-109, an orally delivered consortium of purified Firmicutes spores, reduced recurrence of Clostridioides difficile infection to 12 percent at week 8 compared with 40 percent on placebo in a phase 3 trial, corresponding to sustained clinical response in 88 percent versus 60 percent (Feuerstadt et al., New England Journal of Medicine, 2022). That is a defined consortium hitting a hard clinical endpoint.

What Probiotics Do and Do Not Do

The negative results here are as informative as the positive ones. Zmora and colleagues gave healthy volunteers an eleven-strain probiotic and used upper and lower endoscopy to sample the gut mucosa directly rather than relying on stool. Colonization was person-specific: some individuals permitted it and others resisted it entirely, and stool shedding of the strains did not indicate whether the mucosa had actually been colonized (Cell, 2018). In a companion study, Suez and colleagues found that after a course of antibiotics, the same probiotic delayed the return of the native microbiome toward baseline, while an autologous fecal transplant restored it within days (Cell, 2018).

Neither result says probiotics are useless. Both say that the effect is individual, that stool measurement is a poor readout of what is happening at the mucosa, and that generic supplementation after antibiotics is not obviously the right move.

Fecal Microbiota Transplantation

Fecal microbiota transplantation provides perhaps the strongest evidence that the microbiota causally influences health. In a randomized, double-blind trial of 46 patients with three or more recurrences of C. difficile infection, Kelly and colleagues showed that donor transplantation delivered by colonoscopy outperformed autologous transplantation for resolution of diarrhoea over eight weeks (Annals of Internal Medicine, 2016).

Research has clarified why transplantation works so well for C. difficile: a healthy microbiota maintains ecological conditions including short-chain fatty acid production, lower pH and active bile acid metabolism that suppress C. difficile germination and toxin production. It is worth noting that C. difficile is itself a Firmicute, not a Proteobacterium, which matters because the organisms that suppress it are close relatives competing for the same niche.

Results in other conditions are more mixed. Trials in metabolic disease have reported modest improvements in insulin sensitivity in carefully selected patients, with response correlating with both recipient baseline composition and donor characteristics. In inflammatory bowel disease the picture is genuinely heterogeneous, with some studies showing benefit and others none. That heterogeneity likely reflects the fact that inflammatory bowel disease is not simply a dysbiosis problem; it involves genetic susceptibility, barrier dysfunction and altered mucosal immunity that transplantation alone cannot address.

Diet, Fiber, Polyphenols and Processed Food

Some of the most immediately actionable findings concern the dietary factors that shape microbial community composition and function.

Dietary fiber is essential for maintaining a healthy microbiota, but the nuances matter. Soluble fermentable fibers such as inulin, beta-glucans and pectin are preferentially metabolized by butyrate-producing bacteria, and the Zhao trial showed that only a subset of short-chain fatty acid producers actually responds to a given fiber mix. Different fiber types support different taxa, which is the biological basis for genuinely personalized dietary recommendations rather than generic advice.

Fiber also redirects metabolism, not just composition. Sinha and colleagues showed that dietary fibre steers microbial tryptophan metabolism through interactions within the community, shifting output toward indole-3-propionic acid and related metabolites rather than more putrefactive products (Nature Microbiology, 2024).

Ultra-processed food components have been tested directly in animals. Chassaing and colleagues showed that two commonly used dietary emulsifiers, carboxymethylcellulose and polysorbate-80, altered the mouse gut microbiota, thinned the mucus layer, and promoted low-grade inflammation, colitis in genetically susceptible animals, and metabolic syndrome (Nature, 2015). Suez and colleagues showed that non-caloric artificial sweeteners induced glucose intolerance in mice through microbiota-dependent mechanisms, with a smaller human component (Nature, 2014). Both are animal-first findings and should be described that way.

Dietary environment matters at population scale too. Vangay and colleagues followed immigrants from Southeast Asia to the United States and documented loss of native microbiome diversity, loss of Prevotella dominance and functional shifts that began within months of relocation and compounded across generations (Cell, 2018).

Research suggests that switching from a highly processed diet to a whole-food diet produces measurable shifts in volatile compound production within days, reflecting rapid changes in bacterial metabolism. That responsiveness is what makes near-real-time monitoring of dietary interventions plausible.

Hypothetical scenario. Consider a hypothetical case that follows only the mechanisms above. Someone with type 2 diabetes adopts a diverse fermentable fiber pattern similar in principle to the Zhao trial diet. Over the first two weeks, the mechanisms described would predict a rise in short-chain fatty acid derived volatiles and a fall in branched-chain fatty acids and indolic compounds, well before any change in HbA1c, which reflects roughly three months of glycemia. This scenario is constructed to show why a fast functional readout and a slow clinical one answer different questions. It is not a real patient and not a SNIFR result.

Circadian Rhythms and Temporal Dynamics

The microbiota is not static. It undergoes predictable oscillations in metabolic activity, gene expression and composition across the 24-hour cycle, with specific taxa reaching peak metabolic activity at distinct times corresponding to host feeding and fasting.

Bautista and colleagues review the bidirectional evidence: host circadian timing shapes the microbiota through feeding behavior, immune signaling and epithelial renewal, while microbial metabolites feed back on host circadian physiology. Circadian synchronization appears disrupted in dysbiotic states and in individuals with altered rhythms such as shift workers (Applied Microbiology and Biotechnology, 2025). For VOC analysis specifically, this means a single snapshot may be unrepresentative if not collected at a consistent time.

Microbiota and Aging

How the microbiota changes across the lifespan is one of the more rapidly advancing areas. The ELDERMET study characterized 178 elderly subjects and found that microbiota composition correlated with diet, with residence setting, and with measures of frailty and inflammation, with community-dwelling participants on more varied diets showing more diverse microbiota than long-stay residents (Claesson et al., Nature, 2012).

More recently, Wilmanski and colleagues analyzed gut microbiome, phenotypic and clinical data from more than 9,000 people across three independent cohorts spanning ages 18 to 101. Increasing microbiome uniqueness in later life was associated with healthy ageing markers, and in participants over 85 it was associated with survival over a four-year follow-up (Nature Metabolism, 2021). Uniqueness, notably, was driven by declining Bacteroides dominance rather than by a rise in a specific beneficial taxon.

Animal work has begun establishing causal links, with microbiota transfer between young and aged mice moving markers of age-associated functional decline in both directions. There is also evidence that dietary and lifestyle interventions can partially restore microbiota profiles associated with healthier aging, particularly combinations of higher fiber intake and regular physical activity.

Why Continuous Monitoring Could Accelerate Research

Current microbiome research, for all its sophistication, has a structural limitation: it assesses the microbiota at discrete time points and therefore misses the dynamics. We know the microbiota responds rapidly to diet, stress, medication and circadian cycles, yet our methods usually capture static snapshots.

Continuous volatile monitoring would enable different research questions. Identifying the precise temporal sequence of metabolic changes following an intervention. Characterizing circadian oscillations with better resolution. Identifying individuals whose microbiota is destabilizing before clinical symptoms emerge.

It would also make personalization tractable at scale. As the probiotic colonization studies showed, each individual's microbiota responds differently to intervention, and with episodic assessment truly personalized approaches are difficult to develop.

From Basic Science Toward Precision Medicine

These findings reflect a broader shift in how medicine approaches health: from treating established disease toward maintaining function and intervening earlier. Realizing that requires technology making microbiota assessment non-invasive, accessible and interpretable. VOC analysis is one candidate. Each individual's volatile profile becomes a personal signature, compared against their own baseline rather than a population average.

SNIFR's technology is in development and has not been clinically validated. It is designed to surface patterns and support gut health optimization, with flare-up prediction as a longer-term design goal rather than a demonstrated capability. It is not designed to detect, diagnose or predict any disease. The science here is genuinely exciting, and precisely because of that, overstating it would be a mistake.

Frequently Asked Questions

What are the biggest recent breakthroughs in gut microbiome research?

The most consequential areas are the gut-brain axis, microbial regulation of immune function, the influence of the microbiota on cancer immunotherapy response, and the expansion of the field beyond bacteria to viruses and fungi. What ties them together is a shift from correlation toward mechanism and, in a few cases such as SER-109 for recurrent C. difficile infection, toward randomized clinical endpoints.

How does the gut microbiome affect the brain?

In two population cohorts totalling more than 2,000 people, Valles-Colomer and colleagues found the butyrate producers Faecalibacterium and Coprococcus consistently depleted in people reporting depression. Mechanistic evidence comes largely from animal work, including the demonstration that microbial tryptamine activates an epithelial receptor to change colonic secretion. Translating this to human clinical outcomes remains open.

Does the gut microbiome influence how well cancer treatments work?

Two independent 2018 Science papers found that responders to anti-PD-1 therapy in melanoma had distinct gut microbiota, and that transferring responder stool into germ-free mice improved tumor control. Notably, the two studies named different bacterial species, so the association appears robust while the specific signature does not replicate cleanly. It remains active investigation rather than standard care.

Can diet changes actually improve metabolic disease through the microbiome?

In a randomized trial, Zhao and colleagues found a diverse fermentable fiber diet enriched a specific guild of short-chain fatty acid producers, and 89 percent of the intervention group reached HbA1c below 7 percent versus 50 percent of controls. A separate trial delivering 10 grams a day of an inulin-propionate ester reduced weight gain over 24 weeks. These are research protocols, not general recommendations.

Do probiotics actually work?

It depends heavily on the person and the endpoint. Using endoscopic sampling rather than stool, Zmora and colleagues found that mucosal colonization by an eleven-strain probiotic was person-specific and often absent entirely, and that stool shedding did not indicate colonization. A companion study found probiotics delayed native microbiome recovery after antibiotics, while autologous fecal transplant restored it within days.

What is the virome and why does it matter for gut health?

The virome is the community of viruses in the gut, dominated by bacteriophages that infect bacteria. Research suggests phage communities shift in dysbiotic states and help regulate bacterial diversity, effectively acting as predators that prevent any one species dominating. It matters because a bacteria-only view of the gut misses part of the ecology.

Can gut microbiome monitoring detect dysbiosis before symptoms appear?

That is the aspiration behind continuous monitoring, but it is not an established capability. Observational work in more than 9,000 people has linked microbiome patterns to healthy ageing and survival, which suggests useful signal exists in longitudinal data. Demonstrating a reliable prediction window for digestive symptoms requires prospective datasets that do not yet exist at scale.

References

• Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. New England Journal of Medicine. 2016;375(24):2369-2379. doi:10.1056/NEJMra1600266
• Thaiss CA, Zmora N, Levy M, et al. The microbiome and innate immunity. Nature. 2016;535(7610):65-74. doi:10.1038/nature18847
• Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis. Cell. 2004;118(2):229-241. doi:10.1016/j.cell.2004.07.002
• Sommer F, Bäckhed F. The gut microbiota - masters of host development and physiology. Nature Reviews Microbiology. 2013;11(4):227-238. doi:10.1038/nrmicro2974
• Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nature Microbiology. 2019;4(4):623-632. doi:10.1038/s41564-018-0337-x
• Bhattarai Y, Williams BB, Battaglioli EJ, et al. Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion. Cell Host & Microbe. 2018;23(6):775-785.e5. doi:10.1016/j.chom.2018.05.004
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103. doi:10.1126/science.aan4236
• Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104-108. doi:10.1126/science.aao3290
• Tilg H, Adolph TE, Gerner RR, et al. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. 2018;33(6):954-964. doi:10.1016/j.ccell.2018.03.004
• Zhao L, Zhang F, Ding X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151-1156. doi:10.1126/science.aao5774
• Chambers ES, Viardot A, Psichas A, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015;64(11):1744-1754. doi:10.1136/gutjnl-2014-307913
• Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in Immunology. 2019;10:277. doi:10.3389/fimmu.2019.00277
• Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences. 2008;105(43):16731-16736. doi:10.1073/pnas.0804812105
• Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 2017;5(1):153. doi:10.1186/s40168-017-0373-4
• Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Annals of Internal Medicine. 2016;165(9):609-616. doi:10.7326/M16-0271
• Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. New England Journal of Medicine. 2022;386(3):220-229. doi:10.1056/NEJMoa2106516
• Zmora N, Zilberman-Schapira G, Suez J, et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell. 2018;174(6):1388-1405.e21. doi:10.1016/j.cell.2018.08.041
• Suez J, Zmora N, Zilberman-Schapira G, et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell. 2018;174(6):1406-1423.e16. doi:10.1016/j.cell.2018.08.047
• Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519(7541):92-96. doi:10.1038/nature14232
• Suez J, Korem T, Zeevi D, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014;514(7521):181-186. doi:10.1038/nature13793
• Vangay P, Johnson AJ, Ward TL, et al. US Immigration Westernizes the Human Gut Microbiome. Cell. 2018;175(4):962-972.e10. doi:10.1016/j.cell.2018.10.029
• Sinha AK, Laursen MF, Brinck JE, et al. Dietary fibre directs microbial tryptophan metabolism via metabolic interactions in the gut microbiota. Nature Microbiology. 2024;9(8):1964-1978. doi:10.1038/s41564-024-01737-3
• Bautista J, Ojeda-Mosquera S, Altamirano-Colina A, et al. Bidirectional interactions between circadian rhythms and the gut microbiome. Applied Microbiology and Biotechnology. 2025;109(1):39. doi:10.1007/s00253-025-13570-7
• Wilmanski T, Diener C, Rappaport N, et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nature Metabolism. 2021;3(2):274-286. doi:10.1038/s42255-021-00348-0
• Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488(7410):178-184. doi:10.1038/nature11319
• Ley RE, Peterson DA, Gordon JI. Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine. Cell. 2006;124(4):837-848. doi:10.1016/j.cell.2006.02.017
• Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. Nature Reviews Gastroenterology & Hepatology. 2019;16(1):35-56. doi:10.1038/s41575-018-0061-2

SNIFR is designed to provide insights about gut health patterns, not to diagnose or treat medical conditions. Individual results may vary as gut health is influenced by numerous factors including diet, stress, sleep, and genetics. SNIFR is currently in development, and features described may evolve before commercial release.